Abstract
IntroductionEnhancer of zeste homolog 2 (EZH2) has been reported to be associated with biological malignancy in several cancers. High expression of EZH2 is associated with tumor cell proliferation, invasion and metastasis and has important clinicopathologic significance. However, little is known about the function and mechanisms of EZH2 in cervical cancer. MethodsThis study was conducted to investigate the clinical value of EZH2 expression in cervical cancer and the association between EZH2 and possible downstream proteins using EZH2-targeted interfering RNA. ResultsEZH2 expression rate was significantly greater in cervical cancer tissue than in normal cervical tissue both in mRNA and protein level. High EZH2 expression was significantly associated with differentiation, depth and lymphatic invasion. EZH2 gene RNAi resulted in inhibition of cell growth, cell cycle arrest and decreased ability of invasion in C33A cells. PCNA and MMP-2 expressions were downregulated, whereas p21 was upregulated after inhibition of EZH2. ConclusionsHigh EZH2 expression may be associated with tumor cell proliferation and invasion in cervical cancer, and that EZH2may be one of the candidates for new molecular therapeutic targets for the treatment of cervical cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.